My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 493

    1.

    Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.

    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N; SNK-860 Diabetic Neuropathy Study Group.

    Diabetes Care. 2001 Oct;24(10):1776-82. Erratum in: Diabetes Care 2002 Feb;25(2):413-4. PMID: 11574441 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.

    Jaspan JB, Herold K, Bartkus C.

    Am J Med. 1985 Nov 15;79(5A):24-37.PMID: 3000176 [PubMed - indexed for MEDLINE]Related articles

    3.

    Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.

    Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y.

    Diabetes Care. 2006 Jul;29(7):1538-44.PMID: 16801576 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.

    Jaspan JB, Towle VL, Maselli R, Herold K.

    Metabolism. 1986 Apr;35(4 Suppl 1):83-92.PMID: 3083212 [PubMed - indexed for MEDLINE]Related articles

    5.

    Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.

    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.

    J Diabetes Complications. 1999 May-Jun;13(3):141-50.PMID: 10509874 [PubMed - indexed for MEDLINE]Related articles

    6.

    Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.

    Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B.

    J Diabetes Complications. 1993 Jul-Sep;7(3):170-8.PMID: 8343611 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.

    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.

    Diabetes Res Clin Pract. 2000 Oct;50(2):77-85.PMID: 10960717 [PubMed - indexed for MEDLINE]Related articles

    8.

    Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

    Bril V, Buchanan RA.

    Diabetes Care. 2006 Jan;29(1):68-72.PMID: 16373898 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.

    Valensi P, Le Devehat C, Richard JL, Farez C, Khodabandehlou T, Rosenbloom RA, LeFante C.

    J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.PMID: 16112498 [PubMed - indexed for MEDLINE]Related articles

    10.

    Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.

    Lewin IG, O'Brien IA, Morgan MH, Corrall RJ.

    Diabetologia. 1984 Jun;26(6):445-8.PMID: 6432615 [PubMed - indexed for MEDLINE]Related articles

    11.

    Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.

    Fagius J, Brattberg A, Jameson S, Berne C.

    Diabetologia. 1985 Jun;28(6):323-9.PMID: 3930330 [PubMed - indexed for MEDLINE]Related articles

    12.

    Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.

    Jaspan J, Maselli R, Herold K, Bartkus C.

    Lancet. 1983 Oct 1;2(8353):758-62.PMID: 6137601 [PubMed - indexed for MEDLINE]Related articles

    13.

    The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.

    Christensen JE, Varnek L, Gregersen G.

    Acta Neurol Scand. 1985 Feb;71(2):164-7.PMID: 3920861 [PubMed - indexed for MEDLINE]Related articles

    14.

    WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.

    Airey M, Bennett C, Nicolucci A, Williams R.

    Cochrane Database Syst Rev. 1996 Apr 22;(1):CD002182. Review.PMID: 17636697 [PubMed - indexed for MEDLINE]Related articles

    15.

    Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.

    Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H.

    Free Radic Res. 1999 Sep;31(3):171-9.PMID: 10499773 [PubMed - indexed for MEDLINE]Related articles

    16.

    Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.

    Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, Yasuda Y, Kamiya H, Koh N, Hotta N.

    Diabetes Care. 2001 Jun;24(6):1093-8.PMID: 11375376 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Ranirestat for the management of diabetic sensorimotor polyneuropathy.

    Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group.

    Diabetes Care. 2009 Jul;32(7):1256-60. Epub 2009 Apr 14.PMID: 19366965 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.

    Ziegler D, Mayer P, Rathmann W, Gries FA.

    Diabetes Res Clin Pract. 1991 Oct;14(1):63-73.PMID: 1748064 [PubMed - indexed for MEDLINE]Related articles

    19.

    Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.

    Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, Owens DR, Rosén I, Sönksen P.

    J Diabetes Complications. 1992 Apr-Jun;6(2):123-30.PMID: 1611136 [PubMed - indexed for MEDLINE]Related articles

    20.

    Improvement in peripheral nerve function after one year of Sorbinil.

    Gieron MA, Malone JI, Lowitt S, Korthals JK.

    Neuroreport. 1991 Jun;2(6):348-50.PMID: 1655107 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity